IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Study To Evaluate The Level Of Knowledge Of Pharmacovigilance

Author[1], Author[2], Author[3], Author[4], Author[5]

Ankalge Mangal Madhavrao[1], Bodake Rutuja Sambhaji[2], Atarge Shubham Laxman[3], Karad Shrinivas Yashwant[4], Shaikh Khalid Usman[5]

"1,2,3 Student,Department,Pharmacology,Latur College Of Pharmacy,Hasegaon,Latur,India

4,5,Asst.Professor,,Department,Pharmacology,Latur College Of Pharmacy,Hasegaon,Latur,India

ABSTRACT

Pharmacovigilance supports safe and appropriate use of drugs. Spontaneous reporting of adverse drug reactions (ADRs) is an essential component of pharmacovigilance. However, there is significant underreporting of ADRs. Adverse drug reactions have become a major problem in developing countries. Knowledge of pharmacovigilance could form the basis for interventions aimed at improving reporting rates and decreasing ADRs.

KEYWORDS: Adverse reaction, drug, pharmacovigilance, reporting

INTRODUCTIONS

Pharmacovigilance is an important and integral part of clinical research. Both clinical trials safety and post marketing pharmacovigilance are critical throughout the product lifecycle. Pharmacovigilance is "defined as the pharmacological science relating to the detection, assessment, understanding and prevention of adverse effects, particularly long term and short term adverse effects of medicines." Pharmacovigilance is still in its infancy in India and there exists very limited knowledge about the discipline.

CLINICAL RESEARCH

Clinical research is a branch of medical research that involves people and aims to determine the effectiveness (efficacy) and safety of medications, devices, diagnostic products, and treatment regimens intended for improving human health. These research procedures are designed for the prevention, treatment, diagnosis or understanding of disease symptoms.

Clinical trials are a type of research that studies new tests and treatments and evaluates their effects on human health outcomes. People volunteer to take part in clinical trials to test medical interventions including drugs, cells and other biological products, surgical procedures, radiological procedures, devices, behavioural treatments and preventive care.

There are 3 main phases of clinical trials – phases 1 to 3. Phase 1 trials are the earliest phase trials and phase 3 are later phase trials. Some trials have an earlier stage called phase 0, and there are some phase 4 trials done after a drug has been licensed. Some trials are randomised.

The Drugs Controller General of India (DCGI) is responsible for regulating the quality of drugs, cosmetics, and medical devices in India. The DCGI is the head of the Central Drugs Standard Control Organization.

Functions of the DCGI

- Approves licenses for certain categories of drugs, such as blood products, vaccines, and sera .
- Sets standards for the quality, manufacturing, selling, importing, and distribution of drugs.
- Maintains national reference standards .

Functions of the CDSCO

- Regulates the import, manufacture, distribution, and sale of drugs, cosmetics, and medical devices.
- Approves new drugs and clinical trials.
- Controls the quality of imported drugs.
- Coordinates the activities of state drug control organizations.

Regulatory Application

There are several types of regulatory applications, including:

- Investigational New Drug (IND) Application
  A request to administer an investigational drug or biological product to humans. There are two IND categories: commercial and research.
- New Drug Application (NDA)
  A request to market a new drug in the United States. An NDA is more comprehensive than an IND.
- Abbreviated New Drug Application (ANDA)
  An application for nonprescription drugs.



GOOD CLINICAL PRACTICE

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines ensure the quality and ethics of clinical trials

OBJECTIVES:

- Protecting human subjects: Ensure the rights, safety, and welfare of participants
- Improving data quality: Ensure the reliability and scientific quality of data
- Speeding up new drug development: Reduce the time it takes to market new drugs
- Reducing costs: Lower costs for sponsors and the public

Scope of ICH guidelines

- Quality
  ICH Q10 guidelines help implement quality management systems for pharmaceutical products.
- Safety
  ICH guidelines help identify potential risks like carcinogenicity, genotoxicity, and reprotoxicity.
- Efficacy
  ICH guidelines help ensure that medicines are effective.
- Multidisciplinary
  ICH guidelines include the ICH medical terminology (MedDRA) and the Common Technical Document (CTD).

" The New Drugs and Clinical Trials Rules, 2019" in India encompass the regulation of all new drugs, investigational new drugs for human use, clinical trials, bioequivalence and bioavailability studies, and ethics committees, essentially governing the entire process of testing and approving new drugs within the country, including the ethical considerations involved in clinical trials; it supersedes the previous Part XA and Schedule Y of the Drugs and Cosmetics Rules, 1945.

Objective:

Promotion of research and development in India. Faster accessibility to new drugs. Predictability and transparency in approval process.

Scope of the rules:

- The rules apply to all new drugs, including vaccines, cell-derived products, and gene therapeutic products .
- The rules apply to clinical trials, including academic clinical trials .
- The rules apply to ethics committees, including the composition and training requirements of members .
- The rules apply to biomedical and health research.



Fig. New drugs and clinical trials rules 2019

Protocol Designing For Clinical Trials

clinical trial protocol is a written plan that outlines the steps for conducting a clinical study. It's a vital document that helps ensure the safety of participants and the integrity of the data collected.

Key elements of a clinical trial protocol:

- Background: Rationale for the trial
- Objectives: What the study aims to achieve
- Study design: How the study will be conducted
- Methodology: Detailed information on procedures, measurements, and observations

Process For Clinical Trial Application (CTA):

Clinical Trial Application (CTA) is a Regulatory dossier that is submitted to the Health Authority (HA) of the country in which a sponsor would like to conduct clinical trials with Investigational Medicinal Products (IMPs) or with approved drugs to explore new indications. To obtain clinical trial authorization, a CTA application must be submitted with all the required documentation per the regulations of the competent HA. The regulations and safety reporting requirements for clinical trials vary from one country to another.

CONCEPT OF PHARMACOVIGILANCE

What is Pharmacovigilance?

There is a need to monitor the effects of drugs before and after it‟s successfully tested and launched in the market. Pharmacovigilance involves monitoring and assessing the quality of drugs, detection and preventing of any adverse effects of drugs. Pharmacovigilance involves evaluating information provided by health care providers, pharmaceutical companies and patients in order to understand the risks and benefits involved with a particular drug. Pharmaceutical companies spend millions of dollars and a considerably long time in developing new drugs.

Pharmacovigilance (PV) is the science and practice of monitoring the safety of drugs, from clinical trials through to market use. It involves detecting, assessing, understanding, and preventing adverse effects and other drug-related problems.

The main objectives of pharmacovigilance are to ensure patient safety and to promote the safe use of medicines. It also involves monitoring for adverse drug reactions (ADRs) and communicating findings to the public.

Objectives

- Patient safety: Ensure that patients are safe when taking medicines
- ADR detection: Detect ADRs and other safety issues as early as possible
- Risk assessment: Assess and manage the risks associated with medicines
- Public health: Maintain public health by promoting safe medicine use
- Communication: Communicate findings to the public and stakeholders
- Regulatory compliance: Ensure regulatory compliance for safety monitoring

There are several types of pharmacovigilance, including signal detection, causality assessment, market surveillance, and spontaneous reporting.

Types of pharmacovigilance:

Signal detection: Involves searching for safety signals in data sources, including reported adverse and beneficial events

Causality assessment: Involves evaluating if a drug is the cause of an adverse event

Market surveillance: Involves monitoring drugs after they're on the market, including looking for new adverse reactions

Spontaneous reporting: Involves healthcare providers reporting suspected adverse drug reactions

Drug safety surveillance: Involves monitoring drugs for safety



Fig. objectives of pharmacovigilance

Component Of Pharmacovigilianance

Pharmacovigilance is a science-based activity that monitors adverse drug reactions to protect public health. The components of pharmacovigilance include:

- Risk management
- Periodic safety update reports
- Monitoring suspected adverse reactions
- Pharmacovigilance Risk Assessment Committee
- Pharmacovigilance system Master file
- ADR forms

Constitutional Objective Pharmacovigilance Programe Of India

The Pharmacovigilance Programme of India (PvPI) aims to improve patient safety by monitoring the safety of medicines. The PvPI's objectives include:

- Drug safety: Create a nationwide system for reporting and monitoring drug safety
- Risk-benefit analysis: Analyze the benefit-risk ratio of marketed drugs
- Evidence-based information: Generate evidence-based information on drug safety
- Regulatory support: Support regulatory agencies in making decisions about drug use
- Communication: Communicate safety information to stakeholders to reduce risk

List National Adverse Drugs Monitoring Centers (Amcs)

National ADR Center" typically refers to a national-level organization responsible for managing and facilitating Alternative Dispute Resolution (ADR) mechanisms like mediation and arbitration, with functions including: receiving and managing dispute cases, appointing mediators or arbitrators, conducting training programs for ADR practitioners, devel

oping ADR guidelines, promoting awareness about ADR options, and facilitating communication between disputing parties; some prominent examples include the International Centre for Alternative Dispute Resolution (ICADR) in India and the American Arbitration Association (AAA) in the United States.

INTERNATIONAL CONFERENCE ON HORMONIZATION (ICH) E2E GUIDELINES

elements of non-clinical and clinical safety specifications:

Non-Clinical Safety Specifications

1. Toxicology Studies

- Acute toxicity
- Subchronic toxicity
- Chronic toxicity

2. Pharmacology Studies

- Primary pharmacodynamics
- Secondary pharmacodynamics

3. Genotoxicity Studies

- In vitro studies
- In vivo studies

4. Carcinogenicity Studies

- Long-term studies

5. Reproductive and Developmental Toxicity Studies

- Fertility studies
- Developmental toxicity studies

Clinical Safety Specifications

1. Adverse Event (AE) Reporting

- AE definition: A definition of what constitutes an adverse event.
- AE reporting requirements: Requirements for reporting adverse events, including timing and content.

2. Serious Adverse Event (SAE) Reporting

- SAE definition: A definition of what constitutes a serious adverse event.
- SAE reporting requirements: Requirements for reporting serious adverse events, including timing and content.

3. Clinical Laboratory Tests

- Hematology: Studies to evaluate the effects of a substance on blood cells.
- Clinical chemistry: Studies to evaluate the effects of a substance on blood chemistry.
- Urinalysis: Studies to evaluate the effects of a substance on urine.

4. Vital Signs and Physical Examinations

- Vital signs: Measurements of temperature, pulse, blood pressure, and respiratory rate.
- Physical examinations: Evaluations of the body systems, including the cardiovascular, respiratory, and neurological systems.

5. Electrocardiogram (ECG) and Other Diagnostic Tests

- ECG: A test to evaluate the electrical activity of the heart.
- Other diagnostic tests: Tests to evaluate other bodily functions, such as liver function tests or kidney function tests.

Identification And Evaluation Of Risk Including Drug Drug Interaction And Drug Food Interactions

Identification

Interaction checker applications: Available online, these tools can help identify potential interactions

Databases: The FooDrugs database contains information about potential food-drug interactions

Evaluation

Clinical evaluation: A healthcare provider can assess the risk of an interaction and determine if it's a danger to the patient

Consider patient factors: The risk of an interaction may vary between patients

Consider drug and food factors: The effect of a drug can be altered by the food it's taken



SELECTION OF DRUG CLASS

Selecting a drug class for a pharmacovigilance study involves considering various criteria to ensure the study is both comprehensive and relevant. Here are several factors to consider when choosing a drug class:

1. Commercial Availability

- Widely Available Drugs
- Newly Approved Drugs

2. Sales Volume

- High Sales Volume
- Targeted Use

3. Prevalence of Adverse Events

- Known Safety Concerns
- Emerging Safety Signals

4. Therapeutic Class Importance

- Public Health Impact
- Risk-Benefit Profile

5. Regulatory and Post-Marketing Surveillance

- Regulatory Attention
- Long-Term Use

6. Market Dynamics

- Generic Drugs
- Patent Expiry

7. Population Use

- Pediatric and Elderly Populations
- Pregnancy and Lactation

8. Drug Class with Complex Pharmacokinetics or Pharmacodynamics

Drugs with complex mechanisms of action or those with a narrow therapeutic index (e.g., anticonvulsants, anticoagulants) may be more likely to cause adverse effects, requiring more rigorous monitoring.

9. Patient-Reported Outcomes and Experiences

Some drug classes are linked to patient-reported side effects such as fatigue, mood changes, or quality of life impacts. A study focusing on such outcomes can provide valuable insights into the safety and tolerability of the drug class.

10. Global Considerations

Consider global differences in the drug's use (i.e., cultural, geographic, economic). A drug class that is commonly used in one region may not be used as much in another, influencing the choice of the drug class for a global pharmacovigilance study.

PROFILING OF SELECTED DRUG CLASS

Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism of Action

NSAIDs work by inhibiting the cyclooxygenase (COX) enzymes, which are responsible for the conversion of arachidonic acid into prostaglandins. There are two main types of COX enzymes:

COX-1: Found in most tissues; produces protective prostaglandins involved in gastric mucosa protection, platelet aggregation, and kidney function.

COX-2: Induced during inflammation; produces prostaglandins that mediate pain, fever, and swelling.

Pharmacological Effects

- Analgesic: Reduces pain by inhibiting prostaglandin synthesis.
- Anti-inflammatory: Decreases inflammation in conditions like arthritis.
- Antipyretic: Lowers fever by acting on the hypothalamus.
- Antiplatelet (COX-1 inhibition, e.g., aspirin): Reduces blood clotting, increasing bleeding risk.

Indications

- Pain management (e.g., musculoskeletal pain, headache, dysmenorrhea)
- Inflammatory conditions (e.g., osteoarthritis, rheumatoid arthritis, gout)
- Fever reduction
- Cardiovascular protection (low-dose aspirin for prevention of heart attacks and strokes)

Adverse Effects

- Gastrointestinal (GI): Ulcers, gastritis, GI bleeding, dyspepsia
- Renal: Acute kidney injury, sodium and water retention, hypertension
- Cardiovascular: Increased risk of myocardial infarction and stroke (especially COX-2 selective inhibitors like celecoxib)
- Hematologic: Increased bleeding risk (especially aspirin)
- Hypersensitivity Reactions: Rash, anaphylaxis, aspirin-exacerbated respiratory disease (AERD)

Drug Interactions

- Anticoagulants (e.g., warfarin, heparin): Increased risk of bleeding
- Corticosteroids: Higher risk of GI ulcers and bleeding
- Antihypertensives (e.g., ACE inhibitors, diuretics): Reduced effectiveness and increased kidney damage risk
- Methotrexate: Increased toxicity due to reduced renal clearance
- Lithium: NSAIDs may increase lithium levels, leading to toxicity

Contraindications

- Active peptic ulcer disease or history of GI bleeding
- Severe kidney or liver disease
- Cardiovascular disease (especially for COX-2 inhibitors like celecoxib)
- Aspirin-sensitive asthma
- Pregnancy (especially third trimester due to risk of premature ductus arteriosus closure)

SELECTION OF DRUG

Principles of Drug Selection

1. Indication: Ensure the drug is appropriate for the specific condition.

2. Efficacy: Choose the most effective option based on clinical evidence.

3. Safety: Consider contraindications, side effects, and patient-specific factors (e.g., allergies, pregnancy, renal/hepatic function).

4. Patient Factors: Consider age, comorbidities, adherence potential, and lifestyle.

5. Cost-effectiveness: Select an affordable option without compromising quality.

6. Drug Interactions: Check for interactions with the patient's current medications.

7. Dosage & Administration: Ensure proper dosing, frequency, and route of administration.

8. Regulatory Approval: Confirm that the drug is approved for the intended use.

1. Pharmacy Store Surveys

Visit local pharmacies and inquire about the most frequently sold NSAIDs.

Ask for sales trends over the past months or years.

Identify whether over-the-counter (OTC) or prescription NSAIDs are more popular.

2. Pharmaceutical Company Representatives

Contact medical representatives (MRs) from major pharmaceutical companies.

Ask about sales data and prescribing trends.

Request information on which NSAIDs are most promoted to doctors.

3. Pharmaceutical Company Web Portals & Reports

Check the official websites of major pharma companies for annual sales reports.

Look for drug consumption data and market share insights.

Some companies release reports on best-selling drugs by category.

4. Government & Regulatory Data

National health agencies (e.g., FDA, EMA, CDSCO) may publish drug consumption statistics.

WHO and IMS Health (IQVIA) provide global and regional drug sales data.

Prescription databases and insurance claim reports can offer insights.

5. Market Research Reports

Research firms like IQVIA, Frost & Sullivan, and Statista provide reports on top-selling NSAIDs.

Some reports may require purchase, but summaries can give useful insights.

Commonly Prescribed NSAIDs (Based on Global Trends)

- Ibuprofen – Most used OTC and prescription NSAID for pain and fever.
- Naproxen – Preferred for chronic pain (e.g., arthritis) due to longer half-life.
- Diclofenac – Popular for musculoskeletal pain and inflammation.
- Celecoxib – COX-2 selective NSAID with lower GI risk, widely used for arthritis.
- Aspirin (low-dose) – Commonly prescribed for cardiovascular protection.

IDENTIFICATION OF ADVERSE EFFECTS OF A SELECTED DRUG (EXAMPLE: IBUPROFEN - NSAID)

Methods to Identify Adverse Effects:

1. Literature Review & Clinical Studies:

Refer to research articles, drug monographs, and clinical trial data.

Sources: PubMed, FDA, WHO, and pharmaceutical databases.

2. Pharmacovigilance Reports

Check adverse event reports from regulatory bodies like FDA (FAERS), WHO (VigiBase), and MHRA (Yellow Card Scheme).

3. Patient Reports & Medical Records:

Collect data from hospitals, pharmacies, and electronic health records (EHRs).

4. Surveys & Interviews with Healthcare Professionals:

Conduct discussions with doctors, pharmacists, and nurses about common side effects observed in patients.

5. Spontaneous Reporting Systems (SRS):

National pharmacovigilance programs encourage patients and healthcare professionals to report adverse drug reactions (ADR).

Adverse Effects of Ibuprofen (NSAID Example)

1. Common Adverse Effects (Mild to Moderate)

- Gastrointestinal: Dyspepsia, nausea, heartburn, gastritis
- Renal: Fluid retention, mild kidney dysfunction
- Neurological: Dizziness, headache
- Dermatological: Rash, pruritus

2. Serious Adverse Effects (Severe, but less common)

- Gastrointestinal: Peptic ulcers, GI bleeding, perforation
- Cardiovascular: Hypertension, increased risk of heart attack/stroke (long-term use)
- Renal: Acute kidney injury, nephrotoxicity

3. Long-term Adverse Effects

- Chronic kidney disease (with prolonged use)
- Cardiovascular risks (increased thrombotic events)

IDENTIFICATION OF ADVERSE EFFECTS OF A SELECTED DRUG USING DIFFERENT SEARCH ENGINES

To systematically identify and document the adverse effects of a selected drug (e.g., Ibuprofen), you can use various trusted medical databases and search engine

Step-by-Step Search Approach

1. Use Reliable Drug Information Websites

Here are some widely used medical websites for drug safety and adverse effect profiles:

website	Features
Drugs.com	Compransive drug info, user reviews and FDA alerts
Medscape.com	Detailed clinical information guidelines
RxList.com	FDA-approved drug monographs, side effects , and warnings
Pubmed	Research articles ,clinical studies on drug safety.

2. Search Strategies for Identifying Adverse Effects

- Use targeted search queries on these platforms. Examples:
- “Ibuprofen side effects site:drugs.com” (Google site-specific search)
- “Ibuprofen adverse reactions” (General keyword search)
- “Ibuprofen safety profile Medscape”
- “NSAIDs kidney damage PubMed” (for research-based evidence)

3.Verifying Data Through Pharmacovigilance Reports

- Check FDA's FAERS database for reported side effects.
- Use WHO VigiAccess to see global ADR trends.
- Review EMA (European Medicines Agency) and other national regulatory bodies.

Adverse Drug Reaction (ADR) Monitoring Form

This ADR monitoring form is designed for healthcare professionals to systematically document and report suspected adverse drug reactions.

1. Patient Information

Patient Name: _____

Age: ____ Sex: ☐ Male ☐ Female

Weight: ___ kg

Contact Information (Optional): _____

2. Suspected Drug Information

Generic Name: _____

Brand Name: _____

Dosage & Frequency: _____

Route of Administration: ☐ Oral ☐ IV ☐ IM ☐ SC ☐ Topical ☐ Other: ____

Start Date of Drug: _____

Stop Date (if applicable): _____

3. Description of Adverse Drug Reaction (ADR)

Date of Onset of ADR: _____

Description of Symptoms: (E.g., rash, nausea, dizziness, organ damage, etc.)

Severity: ☐ Mild ☐ Moderate ☐ Severe ☐ Life-threatening

Outcome: ☐ Recovered ☐ Recovering ☐ Not Recovered ☐ Fatal

Action Taken with Drug: ☐ Dose Reduced ☐ Drug Stopped ☐ Continued Same Dose ☐ Other: ____

4. Additional Information

Concomitant Medications (Other drugs patient is taking):

Relevant Medical History (Allergies, Chronic Diseases, etc.):

5. Reporter Information

Name: _____

Designation: ☐ Doctor ☐ Pharmacist ☐ Nurse ☐ Patient ☐ Other: ____

Hospital/Clinic Name: _____

Contact Information (Optional): _____

Date of Report Submission: _____

Submission Details

To Be Reported To: (Hospital ADR Committee / National Pharmacovigilance Center / Regulatory Authority)

Submission Mode: ☐ Online Portal ☐ Email ☐ Paper Submission.

HOSPITAL VISIT

Interaction with Physicians and Nurses for Identifying Unreported ADRs

To identify unreported adverse drug reactions (ADRs) associated with a selected drug (e.g., NSAIDs like Ibuprofen), you can conduct structured interactions with healthcare professionals, such as physicians and nurses.

Step 1: Planning the Interaction

Target Participants

Physicians: General practitioners, specialists (e.g., cardiologists, gastroenterologists, nephrologists).

Nurses: Those in direct patient care, including ICU and surgical ward nurses.

Pharmacists (Optional): Those monitoring prescriptions and drug safety.

Step 2: Conducting Interviews & Surveys

1. Structured Interview Questions

General ADR Awareness:

Have you observed any unexpected side effects related to Ibuprofen/NSAIDs in patients?

Are there any ADRs that you believe are underreported in clinical practice?

Patient Case Reports:

Can you recall any patient cases where an ADR was significant but not officially documented?

How did you manage the adverse effects? (e.g., dose adjustment, discontinuation)

Organ-Specific ADRs:

Have you observed any uncommon renal, hepatic, cardiovascular, or neurological ADRs?

Have patients complained of symptoms that are not listed in standard drug references?

Barriers to ADR Reporting:

What challenges prevent ADR reporting? (e.g., time constraints, lack of awareness, unclear reporting process)

What could improve ADR reporting systems in hospitals?

Step 3: Data Collection Methods

1. Face-to-Face Interviews – Conduct discussions in hospital wards, OPDs, or pharmacies.

2. Online Surveys & Google Forms – Collect responses from a larger sample of physicians/nurses.

3. Focus Group Discussions (FGDs) – Gather multiple healthcare professionals to discuss trends.

4. Anonymous Reporting Boxes – Encourage HCPs to report ADRs without fear of liability.

Patient Interview

Interviewing Patients for Understanding and Identifying Adverse Drug Reactions (ADR)

Patient interviews play a vital role in detecting, documenting, and understanding ADRs, especially those that may go unreported in clinical settings. Below is a structured approach to conducting patient interviews effectively.

1. Ethical Considerations

Obtain informed consent before the interview.

Assure confidentiality of personal health information.

Explain that participation is voluntary and will not affect their treatment

2.Conducting the Patient Interview

1. Patient Demographics

Name (Optional): _____

Age: ____

Sex: ☐

Weight: __ kg

Medical History (e.g., diabetes, hypertension, allergies): _____

Current Medications (including supplements): _____

2. Medication Usage

Drug Name & Dosage: _____

Duration of Use:

☐ Less than a week

☐ 1–4 weeks

☐ More than a month

Are you taking other medications with this drug? ☐ Yes ☐ No

If yes, list them: _____

3. Adverse Drug Reactions (ADR) Experienced

Did you notice any new symptoms after taking this drug? ☐ Yes ☐ No

If yes, what symptoms did you experience? (Check all that apply)

☐ Nausea/Vomiting

☐ Stomach pain or ulcers

☐ Headache/Dizziness

☐ Rash or itching

☐ Swelling (face, hands, legs)

When did the symptoms start after taking the drug?

☐ Immediately

☐ Within a few hours

☐ After a few days

Did you stop taking the drug after experiencing the symptoms? ☐ Yes ☐ No

If yes, did the symptoms improve? ☐ Yes ☐ No

If no, did the symptoms worsen? ☐ Yes ☐ No

4. Impact on Daily Life

Did the ADR affect your daily activities?

☐ Mildly

☐ Moderately

☐ Severely (unable to perform daily tasks)

Did you consult a doctor or pharmacist about this reaction? ☐ Yes ☐ No

If yes, what advice were you given? _____

Have you experienced similar reactions to other medications before? ☐ Yes ☐ No

Step 3: Data Compilation and Analysis

1. Categorize ADRs:

Mild, moderate, or severe

Expected vs. unexpected reactions

Frequency of reported ADRs among patients

2. Identify patterns and trends:

Are certain ADRs more common in specific groups (e.g., elderly, females, patients with kidney disease)?

3. Compare with known ADRs:

Cross-check patient-reported ADRs with official sources like Drugs.com, Medscape, RxList, FDA FAERS database.

4. Report new/unexpected ADRs:

Share findings with pharmacovigilance authorities, hospital committees, or healthcare providers.

Expected Outcomes

Identification of unreported ADRs or unique patient experiences.

Understanding real-world drug safety beyond clinical trials.

Recommendations for improving patient counseling and safer medication use.

Would you like help in structuring a report template to summarize findings from patient interviews?

COLLECTION AND COMPILATION OF DATA

To systematically collect and compile ADR data, follow these structured steps:

Step 1: Data Collection Process

1. Identify Data Sources

- Patient Interviews: Gather ADR reports from patients using a structured questionnaire.
- Physician/Nurse Feedback: Obtain clinical observations and case reports.
- Pharmacy Reports: Identify frequently reported ADRs for specific drugs.
- Hospital Records & Pharmacovigilance Data: Analyze documented ADR cases.

2. Use a Standardized ADR Reporting Form

- Patient demographics (age, gender, medical history).
- Drug details (name, dose, duration, co-medications).
- ADR description (onset, severity, affected organ system).
- Management of ADR (dose adjustment, discontinuation, treatment).
- Naranjo Scale assessment (score and classification).

Step 2: Compiling Data into a Database or Spreadsheet

Categorize ADRs by Severity & Frequency

- Mild ADRs: Nausea, headache, dizziness.
- Moderate ADRs: GI bleeding, allergic reactions, elevated liver enzymes.
- Severe ADRs: Anaphylaxis, renal failure, cardiovascular events.

Step 3: Analyzing and Interpreting Data

- Calculate the percentage of ADRs categorized as Definite, Probable, Possible, or Doubtful.
- Identify the most commonly affected organ systems (e.g., GI, renal, cardiovascular).
- Compare findings with existing ADR reports from sources like Drugs.com, WHO Vigibase, FDA FAERS.
- Identify unreported or rare ADR patterns that require further investigation.

Step 4: Reporting and Presentation

- Graphical Representation:
- Pie charts for ADR causality distribution (Definite, Probable, Possible).
- Bar graphs showing ADR frequency per drug.
- Summary Report for Pharmacovigilance Authorities:
- Total ADR cases recorded
- Most affected patient groups (e.g., elderly, those with comorbidities)
- Recommendations for safer drug use

CONCLUSION

The conclusion of pharmacovigilance emphasizes its critical role in ensuring drug safety and protecting public health. By continuously monitoring, detecting, assessing, and preventing adverse drug reactions (ADRs) and other drug-related issues, pharmacovigilance helps improve patient safety and regulatory decision-making.

Ongoing advancements in technology, data analytics, and global collaboration are enhancing pharmacovigilance practices, leading to more efficient detection of potential risks. However, challenges such as underreporting, data integration, and evolving drug safety concerns require continuous improvement and vigilance.

Ultimately, pharmacovigilance is a dynamic and essential field that supports the safe and effective use of medicines, benefiting both healthcare professionals and patients worldwide.

ACKNOWLEDGMENTS

I would like to express my sincere gratitude to all individuals and organizations who have contributed to the understanding and advancement of pharmacovigilance.

First and foremost, I extend my appreciation to healthcare professionals, researchers, and regulatory authorities for their relentless efforts in monitoring and ensuring drug safety. Their dedication to reporting adverse drug reactions (ADRs) and analyzing safety data plays a crucial role in protecting public health.

I also acknowledge the contributions of pharmaceutical companies, academic institutions, and global health organizations that work collaboratively to enhance pharmacovigilance systems and promote safer medication use.

A special thank you to patients and the general public who actively participate in reporting adverse effects, as their involvement is essential in strengthening drug safety monitoring.

Lastly, I am grateful for the advancements in technology and data analytics that continue to improve phrmacovigilance practices, making drug safety monitoring more efficient and effective.

Thank you to everyone committed to the mission of pharmacovigilance—ensuring the safe and responsible use of medicines worldwide.

REFERENCE

1.Tripathi DK, Shiv S. Pharmacovigilance (Nirali Prakashan). and others, editor; 2017. p. 262.

2. Dr R. history And Development of pharmacovigilance. and others, editor;. p. 1–10.

3. Nimesh S. Pharmacovigilance program of review article Acta scientific pharmaceutical sciences; 2022.

4. Sahu RK, Yadav R. Adverse drug reaction monitoring prospects and impending challenges for pharmacovigilance.

5. achdev Y. Pharmacovigilance safety matter, Indian pharmacology; 2008.

6.. Mohiuddin AK. Department Of pharmacy, world University of Bangladesh, green road, Dhaka , Bangladesh.

7. Caffrey S, Paul C. Generic drugs – The Indian scenario. J Postgrad Med. 2019;65(2):67–9.

9. Lakshmi I, Aashritha M. A review on pharmacovigilance and its importance. Teja A World J Pharm Pharma Sci. 2017;6(1):300

10. Lazarou J, Pomeranz BH, Corey PN; Incidence of Adverse Drug Reactions in

hospitalized patients. JAMA, 198; 279: 1200-1205.

11. Bord CA, Rachi CL; Adverse Drug Reactions in United States Hospitals.

Pharmacotherapy, 2006; 26(5): 601-08.

12. World Health Organiation(WHO), Uppsala Monitoring Centre(internet). The use of

WHO-UMC system for standard case causality assessment available at http://www.who

umc.org/graphics/4409.pdf.

13. Macedo AF, Marques FB, Ribeiro CF, Texeira F. Causality assessment of adverse drug

reactions: comparision of the results obtsined from published decisional algorithms and

from the evaluations of an expert panel. Pharmacoepidemiological drug sof., 2005; 14:

885-890.

14. Arimone Y, Begnad B, Miremont, Salame G, Fourrier-Regalt A, Moore N, Molimard M

et al, agreement of expert judgment in causality assessment of adverse drug reactions. Eur

J Clin pharmacology, 2005; 61: 169-173.

15. Joerg H. Basic principles of pharmacovigilance and data sources.

16. Sachdev Y. pharmacovigilance: safety matters, Indian pharmacology. February 2008; 40.9. Hall et al. 1995; Horbuckle et al. 1999; Tuntti and Neuroren 2002.